2-[4-(4-氟苯基)-1-哌嗪基]乙胺 | 27144-84-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 2-[4-(4-氟苯基)-1-哌嗪基]乙胺
• 中文别名: 2-[4-（4-氟苯基）哌嗪-1-基]乙胺
• 英文名称: 2-[4-(4-fluoro-phenyl)-piperazin-1-yl]-ethylamine
• 英文别名: 2-<4-(4-Fluorphenyl)-1-piperazinyl>-ethylamin；2-[4-(4-Fluorphenyl)-1-piperazinyl]-ethylamin；2-[4-(4-Fluorophenyl)piperazin-1-yl]ethanamine
• CAS: 27144-84-9
• 化学式: C₁₂H₁₈FN₃
• mdl: MFCD09723204
• 分子量: 223.293
• InChiKey: ARMGEGHYHDTIII-UHFFFAOYSA-N

物化性质

• 沸点：
  138-142 °C(Press: 0.05 Torr)
• 密度：
  1.126±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  32.5
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  2-[4-(4-氟苯基)-1-哌嗪基]乙胺 在 molecular sieve 、 4 A molecular sieve 、 三乙酰氧基硼氢化钠 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 2-[4-(4-fluorophenyl)piperazin-1-yl]-N-[[3-(2-methoxyphenyl)-1,2-oxazol-5-yl]methyl]-N-methylethanamine
  参考文献：
  名称：

  Synthesis and biological evaluation of novel T-type Ca2+ channel blockers

  摘要：

  A small molecule library of piperazinylalkylisoxazole derivatives containing about 600 compounds was designed, synthesized and evaluated for blocking effects on T-type Ca2+ channel. Several ligands were identified to possess high inhibitory activity against the T-type Ca2+ channel. The compound 21 with trifluoromethyl substituents at C-3-position of phenyl group (W) and C-2-position of phenyl group (R-2) showed the highest inhibitory activity with IC50 value of 1.02 muM, which is comparable to that of mibefradil. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.06.011
• 作为产物：
  描述：

  2-(2-(4-(4-氟苯基)哌嗪-1-基)乙基)异吲哚啉-1,3-二酮 在 一水合肼 作用下， 以 乙醇 为溶剂， 生成 2-[4-(4-氟苯基)-1-哌嗪基]乙胺
  参考文献：
  名称：

  ZM241385衍生物在人腺苷A2A受体上的结合动力学

  摘要：

  经典药物的设计和开发主要依赖于亲和力或效价驱动的结构-活性关系（SAR）。迄今为止，给定化合物的结合动力学已被很大程度上忽略，其重要性现在越来越被人们所认识。在本研究中，除了对腺苷A 2A受体（A 2A R）进行传统的SAR分析外，我们还进行了广泛的结构动力学关系（SKR）研究。由24 A 2A R化合物组成的化合物，所有三唑三嗪衍生物均类似于原型拮抗剂ZM241385（4-（2-（（7-氨基-2-（呋喃-2-基）-[1,2,4]三唑[1， 5一] [1,3,5] triazin-5-基）氨基）乙基）苯酚）在亲和力上仅显示微小差异，尽管它们与受体的解离速率差异很大。我们相信，像我们对A 2A R所做的那样，SKR和SAR分析的这种结合对于G蛋白偶联受体的超家族将具有普遍的重要性，因为它可以作为调整配体之间相互作用的新策略和受体。

  DOI：

  10.1002/cmdc.201300474

文献信息

• Synthesis and Structure−Activity Relationships of a New Model of Arylpiperazines. 4. 1-[ω-(4-Arylpiperazin-1-yl)alkyl]-3-(diphenylmethylene)- 2,5-pyrrolidinediones and -3-(9<i>H</i>-fluoren-9-ylidene)-2,5-pyrrolidinediones: Study of the Steric Requirements of the Terminal Amide Fragment on 5-HT_1A Affinity/Selectivity
  作者：María L. López-Rodríguez、M. José Morcillo、Tandú K. Rovat、Esther Fernández、Bruno Vicente、Antonio M. Sanz、Medardo Hernández、Luis Orensanz

  DOI：10.1021/jm980285e

  日期：1999.1.1

  demonstrated moderate to high affinity for 5-HT1A and alpha1 receptor binding sites but had no affinity for D2 receptors. The study of the length of the alkyl chain and the imide substructure has allowed us to suggest some differences between the 5-HT1A and the alpha1-adrenergic receptors: (i) for III and IV, affinity for the 5-HT1A receptor as a function of the length of the methylene linker decreases

  在本文中，我们报告了一系列新的1- [ω-（4-芳基哌嗪-1-基）烷基] -3-（二苯基亚甲基）- 2、2-吡咯烷二酮（III）（1-4）和-3-（9H-芴-9-亚烷基）-2、5-吡咯烷二酮（IV）（1-4），其中烷基连接基包含1-4亚甲基和芳基被不同地取代。将获得的结果与先前报道的双环乙内酰脲（I）和相关双环胺（II）系列的结果进行比较。被测化合物1-4的相当一部分对5-HT1A和α1受体结合位点表现出中等至高亲和力，但对D2受体没有亲和力。对烷基链长度和酰亚胺亚结构的研究使我们提出了5-HT1A和α1-肾上腺素受体之间的一些区别：（i）对于III和IV，对5-HT1A受体的亲和力随亚甲基接头长度的变化而降低，顺序为4> 1 >> 3约2，而对α1受体的亲和力则按3顺序降低。 4> 1约2; （ii）5-HT1A受体中的无药效位阻性口袋（不保留配体的药效团但保留分子的非必需片段的受体区）
• Chemical Modifications on 4-Arylpiperazine-Ethyl Carboxamide Derivatives Differentially Modulate Affinity for 5-HT1A, D4.2, and α2A Receptors: Synthesis and In Vitro Radioligand Binding Studies
  作者：Amaury Graulich、Marc Léonard、Mélissa Résimont、Xi-Ping Huang、Bryan L. Roth、Jean-François Liégeois

  DOI：10.1071/ch09353

  日期：——

  A series of substituted 4-aryl-piperazine-ethyl heteroarylcarboxamides were prepared and tested in in vitro radioligand binding studies. The presence of a quinoxaline has a favourable impact in terms of serotonin 5-HT1A versus dopamine D4.2 receptor selectivity. Compounds with a 3-CF3 group at the distal phenyl ring are the most effective in terms of affinity and selectivity for 5-HT1A versus D4.2 receptors. A 4-phenyl-1,2,3,6-tetrahydropyridine in place of the corresponding 4-phenyl-piperazine side chain is also favourable not only for the affinity for 5-HT1A and D4.2 receptors but also in some cases for α 2A-adrenoceptors.

  我们制备了一系列取代的 4-芳基哌嗪-乙基杂芳基羧酰胺，并在体外放射性配体结合研究中进行了测试。喹喔啉的存在对血清素 5-HT1A 与多巴胺 D4.2 受体的选择性具有有利影响。就对 5-HT1A 受体和 D4.2 受体的亲和力和选择性而言，远端苯环上带有 3-CF3 基团的化合物最为有效。用 4-苯基-1,2,3,6-四氢吡啶取代相应的 4-苯基-哌嗪侧链也不仅有利于提高对 5-HT1A 和 D4.2 受体的亲和力，而且在某些情况下还有利于提高对 α 2A 肾上腺素受体的亲和力。
• Isoxazole Derivatives and Use Thereof
  申请人：Cho Jeong Woo

  公开号：US20090131336A1

  公开（公告）日：2009-05-21

  Disclosed herein are isoxazole derivaties and uses thereof. Serving as agonists of Wnt, the isoxazole derivatives activate Wnt/β-catenin signaling and thus can be used in the treatment and prevention of diseases related to the signal transduction. Also, pharmaceutically acceptable salts of the isoxazole derivatives are disclosed.

  本文披露了异噁唑衍生物及其用途。作为Wnt的激动剂，异噁唑衍生物激活Wnt/β-连环蛋白信号传导，因此可用于治疗和预防与信号传导相关的疾病。此外，还披露了异噁唑衍生物的药用盐。
• 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases
  申请人：Boettcher Andreas

  公开号：US20100125064A1

  公开（公告）日：2010-05-20

  The invention relates to 3-heterocyclyl indolyl compounds capable of inhibiting the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively, said compounds having the formula I, wherein R 1 , R 2 , R 3 , R 4 , R A , Y and Y are as defined in the specification. Due to their activity, the compounds are useful in the treatment of various disorders and diseases mediated by the activity of MDM2 and/or MDM4, or variants thereof, such as inflammatory or proliferative diseases or in the protection of cells.

  本发明涉及能够抑制p53或其变体与MDM2和/或MDM4或其变体相互作用的3-杂环基吲哚化合物，其中所述化合物具有式I，其中R1、R2、R3、R4、RA、Y和Y的定义见说明书。由于其活性，这些化合物可用于治疗由MDM2和/或MDM4或其变体介导的各种疾病和疾病，例如炎症性或增殖性疾病或细胞保护。
• Synthesis and biological evaluation of oxazole derivatives as T-type calcium channel blockers
  作者：Jie Eun Lee、Hun Yeong Koh、Seon Hee Seo、Yi Yeon Baek、Hyewhon Rhim、Yong Seo Cho、Hyunah Choo、Ae Nim Pae

  DOI：10.1016/j.bmcl.2010.05.030

  日期：2010.7

  T-type calcium channel is one of therapeutic targets for the treatment of cardiovascular diseases and neuropathic pain. In this study, as a part of our ongoing efforts to develop potent T-type calcium channel blockers, we designed oxazole derivatives substituted with arylpiperazinylalkylamines. The oxazoles were synthesized in a convenient convergent synthetic method, and biologically evaluated against alpha(1G) (Ca(V)3.1) T-type calcium channel. Among total 41 oxazole compounds synthesized, the most active one was the compound 10-35 with an IC(50) value of 0.65 mu M, which is comparable with that of mibefradil. (C) 2010 Elsevier Ltd. All rights reserved.